Cyprus Mail
BusinessInternational

BioNTech strengthens cancer therapy expertise with US acquisition

biontech 2 vaccine

BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of US biotech company Gilead (GILD.O) to expand its footprint in north America and in novel cancer treatments.

The German biotech firm on Monday said it was buying a solid tumour neoantigen T-cell receptor therapy (TCR-Ts) R&D platform and a manufacturing plant in the city of Gaithersburg in the state of Maryland from Kite Pharma.

T-cell receptors (TCRs) are a class of compounds that make it easier for the body’s immune cells to identify and destroy cancer cells, while TCR-Ts detect targets both inside and outside the cancer cells.

The acquisition will expand BioNTech’s pipeline in individualized cell therapies for cancer patients and add to its existing manufacturing capacities in Idar-Oberstein, Germany, it said.

Kite Pharma will receive a one-time upfront payment, BioNtech said without giving further details.

The deal is expected to close by the end of July, 2021.

Follow the Cyprus Mail on Google News

Related Posts

Winners of Stelios bicommunal awards announced

Tom Cleaver

Electricity authority finds illegal solar installations

Staff Reporter

Cyprus sees ‘one of the largest increases’ in renewable energy share

Tom Cleaver

“Nurturing the talents of tomorrow”: Adsterra Backs Up the 2nd Youth Tech Fest Cyprus 2024

Souzana Psara

Comparing European loans: What borrowers need to know

CM Guest Columnist

Oil extends losses on easing Middle East tension, demand concerns

Reuters News Service